Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
British Journal of Clinical Pharmacology|December 31, 2024
Population modelling of nilotinib exposure vs. longitudinal BCR::ABL1 response in patients with chronic phase chronic myeloid leukaemia using a semimechanistic disease modelSherwin K B Sy, Deok Yong Yoon, Christelle Darstein, et al.
The Annals of Pharmacotherapy|January 6, 2005
Obesity does not alter the pharmacokinetics of drotrecogin alfa (activated) in severe sepsisHoward Levy, David Small, Darell E Heiselman, et al.
European Heart Journal|April 20, 2006
Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery diseaseTomas Jernberg, Christopher D Payne, Kenneth J Winters, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|December 4, 2009
Carboplatin and paclitaxel in combination with oral enzastaurin in advanced ovarian or primary peritoneal cancer: results from a safety lead-in studyIgnace Vergote, Frederic Amant, Gülten Oskay-Oezcelik, et al.
Cancer Chemotherapy and Pharmacology|February 28, 2025
Population pharmacokinetic modeling of asciminib in support of exposure-response and ethnic sensitivity analyses in patients with chronic myeloid leukemiaChristelle Darstein, Deokyong Yoon, Yiqun Yang, et al.
Clinical Pharmacokinetics|February 11, 2026
Leveraging Model-Informed Drug Development to Predict Asciminib Efficacy in Second-Line Treatment of Chronic Myeloid Leukemia in Chronic PhaseSherwin K B Sy, Deok Yong Yoon, Yiqun Yang, et al.
Cancer Chemotherapy and Pharmacology|December 12, 2018
Octreotide SC depot in patients with acromegaly and functioning neuroendocrine tumors: a phase 2, multicenter studyMarianne Pavel, Françoise Borson-Chazot, Anne Cailleux, et al.
Endocrine|November 6, 2021
Combination of pasireotide and octreotide: effects on GH and IGF-I secretion and glucose metabolism in healthy volunteersLibuse Tauchmanova, Astrid Breitschaft, Geoffrey Holder, et al.
Clinical Drug Investigation|February 4, 2017
Drug Interaction Potential of Osilodrostat (LCI699) Based on Its Effect on the Pharmacokinetics of Probe Drugs of Cytochrome P450 Enzymes in Healthy AdultsSara Armani, Lillian Ting, Nicholas Sauter, et al.
Anti-Cancer Drugs|November 29, 2007
A phase I safety, tolerability, and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced solid tumorsD Ross Camidge, S Gail Eckhardt, Lia Gore, et al.
Pageof 3